Immediate Impact
1 from Science/Nature 80 standout
Citing Papers
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial
2023 Standout
Pharmacology and Clinical Development of Factor XI Inhibitors
2023 Standout
Works of C. Dansirikul being referenced
A phase I, randomized, proof‐of‐clinical‐mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers
2017
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non‐valvular atrial fibrillation from the RE‐LY trial
2011
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| C. Dansirikul | 41 | 277 | 20 | 138 | 56 | 12 | 473 | |
| Claire Gozalo | 32 | 86 | 2 | 59 | 62 | 32 | 463 | |
| Bruno Boutouyrie | 56 | 239 | 16 | 251 | 17 | 15 | 421 | |
| Amy J. Hatfield | 16 | 198 | 5 | 83 | 12 | 9 | 562 | |
| T. W. B. Gehr | 65 | 130 | 31 | 160 | 18 | 560 | ||
| Klaus Moerike | 21 | 145 | 8 | 21 | 102 | 6 | 570 | |
| Mona Razavian | 11 | 174 | 2 | 37 | 25 | 7 | 458 | |
| Erik van Meegen | 3 | 246 | 17 | 102 | 16 | 12 | 465 | |
| J.J. Thebault | 2 | 208 | 22 | 138 | 37 | 22 | 531 | |
| Aileen B Luzier | 3 | 237 | 6 | 27 | 45 | 17 | 470 | |
| Pieter De Kesel | 13 | 40 | 7 | 51 | 81 | 18 | 537 |
All Works
Loading papers...